HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

YZYBIO-B

7.240

0.000

Volume:- -

Turnover:- -

Market Cap:1.40B

PE:-14.38

High:7.240

Open:7.240

Low:7.240

Close:7.240

52wk High:8.350

52wk Low:4.000

Shares:193.85M

HK Float Shares:111.47M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.503

ROE:-704.81%

ROA:-18.74%

PB:-45.16

PE(LYR):-14.38

PS:8.30

Loading ...

Overview Company News Filings

Wuhan YZY Biopharma (2496) Releases Further Details on Land and Building Transfer

Bulletin Express

Wuhan Yzy Biopharma Sells Land Use Right and Building

YZYBIO-B (02496) Receives HKEX Approval for Full H-Share Circulation

Wuhan Yzy Biopharma Says M701 Receives IND Approval From FDA

Wuhan YZY Biopharma Gets Trial Nod for Malignant Pleural Effusion Drug from US FDA

MT Newswires Live

YZYBIO-B (02496): M 701 Receives FDA IND Approval

Wuhan YZY Biopharma - M701 Receives Ind Approval From FDA

THOMSON REUTERS

Wuhan YZY Biopharma Receives FDA IND Approval for M701 Clinical Trials

YZYBIO-B (02496): China Securities Regulatory Commission Issues Filing Notice for Company's H-Share Full Circulation

Wuhan YZY Biopharma Submits CSRC Filing for H Share Full Circulation

Wuhan Yzy Biopharma Sells Land Use Right and Building to Wuhan Yiruide

BRIEF-Wuhan YZY Biopharma Says Wuhan Yiruide To Buy Land Use Right And Building

YZYBIO-B (02496) Plans to Transfer Land Use Rights and Buildings in Wuhan East Lake High-Tech Zone for RMB 36.88 Million

Wuhan YZY Biopharma (2496) Announces Discloseable Transaction for Transferring Land Use Right and Building to Wuhan Yiruide

Bulletin Express

Wuhan YZY Biopharma Co Ltd - Wuhan Yiruide to Buy Land Use Right and Building for RMB36.9 Mln

THOMSON REUTERS

YZYBIO-B (02496): Shi Jian Elected as Employee Representative Supervisor

Wuhan YZY Biopharma Appoints New Employee Representative Supervisor

YZYBIO-B (02496): Y225 (Emicizumab Injection) Receives IND Approval from NMPA

Wuhan YZY Biopharma - Y225 ‘‘Emicizumab Injection" Receives Ind Approval From Nmpa

THOMSON REUTERS

Wuhan YZY Biopharma Receives NMPA IND Approval for Y225 Emicizumab Injection

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02496/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02496","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02496\",,,,,undefined,":{"symbol":"02496","market":"HK","secType":"STK","nameCN":"YZYBIO-B","latestPrice":7.24,"timestamp":1770945213892,"preClose":7.24,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":111468814,"shares":193849200,"eps":-0.503479,"marketStatus":"Trading","change":0,"latestTime":"02-13 10:31:42","open":7.24,"high":7.24,"low":7.24,"amount":0,"amplitude":0,"askPrice":8.32,"askSize":600,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.441123,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1770955200000},"marketStatusCode":2,"adr":0,"listingDate":1695571200000,"exchange":"SEHK","adjPreClose":7.24,"openAndCloseTimeList":[[1770946200000,1770955200000],[1770958800000,1770969600000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02496\",,,,,undefined,":{"symbol":"02496","floatShares":111468814,"roa":"-18.74%","roe":"-704.81%","lyrEps":-0.503479,"shares":193849200,"dividePrice":0,"high":7.24,"amplitude":0,"preClose":7.24,"low":7.24,"week52Low":4,"pbRate":"-45.16","psRate":"8.30","week52High":8.35,"institutionHeld":0,"latestPrice":7.24,"committee":-1,"eps":-0.503479,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.441123,"open":7.24,"prevYearClose":8.02,"prevWeekClose":7.6,"prevMonthClose":7.87,"prevQuarterClose":8.02,"fiveDayClose":7.6,"twentyDayClose":7.86,"sixtyDayClose":7.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02496\",params:#limit:5,,,undefined,":[{"date":"2025-08-26","symbol":"02496","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null},{"date":"2025-03-28","symbol":"02496","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"Post Market","dateTimestamp":1743091200000,"actualEps":null},{"date":"2024-08-29","symbol":"02496","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724895000000,"name":null,"time":"","dateTimestamp":1724860800000,"actualEps":null},{"date":"2024-03-28","symbol":"02496","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711589400000,"name":null,"time":"","dateTimestamp":1711555200000,"actualEps":null},{"date":"2023-09-28","symbol":"02496","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1695864600000,"name":null,"time":"","dateTimestamp":1695830400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02496\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02496\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02496\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02496","date":"2026-02-12","current":-16.412656,"percent":0.130508,"low":-18.565593,"twenty":-13.585714,"median":-8.127348,"eighty":-6.88926,"high":-3.741546,"avg":-9.374087,"sd":3.79541,"marketCap":1403468208},"quantilePoints":[{"date":"2023-09-22","current":-15.261024,"twenty":-15.274233,"median":-15.26928,"eighty":-15.264326,"marketCap":3088019200},{"date":"2023-09-29","current":-15.292224,"twenty":-17.099581,"median":-15.293234,"eighty":-15.280473,"marketCap":3049418960},{"date":"2023-10-06","current":-15.493216,"twenty":-15.501023,"median":-15.292224,"eighty":-15.050323,"marketCap":3088019200},{"date":"2023-10-13","current":-15.380625,"twenty":-15.493216,"median":-15.348538,"eighty":-15.261024,"marketCap":3060999032},{"date":"2023-10-20","current":-10.535817,"twenty":-15.418704,"median":-15.300038,"eighty":-14.801616,"marketCap":2093571360},{"date":"2023-10-27","current":-9.759574,"twenty":-15.417248,"median":-15.292224,"eighty":-11.937608,"marketCap":1938492000},{"date":"2023-11-03","current":-9.733728,"twenty":-15.412338,"median":-15.155674,"eighty":-10.478048,"marketCap":1938492000},{"date":"2023-11-10","current":-8.275398,"twenty":-15.390041,"median":-14.508961,"eighty":-9.494912,"marketCap":1647718200},{"date":"2023-11-17","current":-8.703164,"twenty":-15.38145,"median":-11.695259,"eighty":-8.750672,"marketCap":1748519784},{"date":"2023-11-24","current":-8.421561,"twenty":-15.329285,"median":-10.573898,"eighty":-8.701771,"marketCap":1705872960},{"date":"2023-12-01","current":-7.919793,"twenty":-15.30332,"median":-10.003273,"eighty":-8.541365,"marketCap":1610886852},{"date":"2023-12-08","current":-8.497372,"twenty":-15.294595,"median":-9.516549,"eighty":-8.420238,"marketCap":1721380896},{"date":"2023-12-15","current":-8.258301,"twenty":-15.292426,"median":-9.276148,"eighty":-8.274722,"marketCap":1682611056},{"date":"2023-12-22","current":-8.349506,"twenty":-15.280473,"median":-8.776546,"eighty":-8.277258,"marketCap":1700057484},{"date":"2023-12-29","current":-8.428335,"twenty":-15.270931,"median":-8.740745,"eighty":-8.306436,"marketCap":1725257880},{"date":"2024-01-05","current":-8.249766,"twenty":-15.218884,"median":-8.699682,"eighty":-8.272694,"marketCap":1676795580},{"date":"2024-01-12","current":-8.302569,"twenty":-15.000582,"median":-8.571321,"eighty":-8.275563,"marketCap":1688426532},{"date":"2024-01-19","current":-8.113537,"twenty":-14.743085,"median":-8.513713,"eighty":-8.272694,"marketCap":1647718200},{"date":"2024-01-26","current":-7.982332,"twenty":-14.471602,"median":-8.481448,"eighty":-8.258393,"marketCap":1614763836},{"date":"2024-02-02","current":-7.992522,"twenty":-13.915342,"median":-8.424948,"eighty":-8.196137,"marketCap":1614763836},{"date":"2024-02-09","current":-8.02019,"twenty":-12.050937,"median":-8.406699,"eighty":-8.080173,"marketCap":1628333280},{"date":"2024-02-16","current":-8.343013,"twenty":-11.339581,"median":-8.370574,"eighty":-8.105196,"marketCap":1694242008},{"date":"2024-02-23","current":-8.30086,"twenty":-10.803844,"median":-8.369483,"eighty":-8.124586,"marketCap":1676795580},{"date":"2024-03-01","current":-8.247733,"twenty":-10.604956,"median":-8.362825,"eighty":-8.153154,"marketCap":1667103120},{"date":"2024-03-08","current":-8.186551,"twenty":-10.543433,"median":-8.343013,"eighty":-8.173812,"marketCap":1655472168},{"date":"2024-03-15","current":-8.155425,"twenty":-10.30474,"median":-8.311389,"eighty":-8.173276,"marketCap":1647718200},{"date":"2024-03-22","current":-7.39462,"twenty":-9.857053,"median":-8.302569,"eighty":-8.105196,"marketCap":1492638840},{"date":"2024-03-28","current":-7.61103,"twenty":-9.744066,"median":-8.301568,"eighty":-8.043049,"marketCap":1531408680},{"date":"2024-04-05","current":-7.288366,"twenty":-9.690292,"median":-8.300787,"eighty":-8.021295,"marketCap":1512023760},{"date":"2024-04-12","current":-6.976051,"twenty":-9.494912,"median":-8.295352,"eighty":-7.983468,"marketCap":1448053524},{"date":"2024-04-19","current":-6.963318,"twenty":-9.388856,"median":-8.276973,"eighty":-7.977458,"marketCap":1444176540},{"date":"2024-04-26","current":-6.971914,"twenty":-9.296949,"median":-8.272018,"eighty":-7.930221,"marketCap":1444176540},{"date":"2024-05-03","current":-6.976736,"twenty":-9.241479,"median":-8.264756,"eighty":-7.6347,"marketCap":1444176540},{"date":"2024-05-10","current":-6.960212,"twenty":-8.933122,"median":-8.256463,"eighty":-7.598809,"marketCap":1444176540},{"date":"2024-05-17","current":-6.970443,"twenty":-8.807861,"median":-8.251559,"eighty":-7.39462,"marketCap":1444176540},{"date":"2024-05-24","current":-7.095514,"twenty":-8.76114,"median":-8.247733,"eighty":-7.267873,"marketCap":1444176540},{"date":"2024-05-31","current":-7.0883,"twenty":-8.730819,"median":-8.237322,"eighty":-7.171233,"marketCap":1444176540},{"date":"2024-06-07","current":-7.097101,"twenty":-8.707372,"median":-8.195562,"eighty":-7.097101,"marketCap":1444176540},{"date":"2024-06-14","current":-7.132215,"twenty":-8.698985,"median":-8.193432,"eighty":-7.097238,"marketCap":1449992016},{"date":"2024-06-21","current":-7.988022,"twenty":-8.625304,"median":-8.18531,"eighty":-7.098087,"marketCap":1620579312},{"date":"2024-06-28","current":-7.48471,"twenty":-8.574009,"median":-8.177364,"eighty":-7.098775,"marketCap":1517839236},{"date":"2024-07-05","current":-7.715801,"twenty":-8.562528,"median":-8.159606,"eighty":-7.101937,"marketCap":1564363044},{"date":"2024-07-12","current":-7.141207,"twenty":-8.536784,"median":-8.120442,"eighty":-7.107036,"marketCap":1449992016},{"date":"2024-07-19","current":-7.131527,"twenty":-8.514561,"median":-8.053748,"eighty":-7.107036,"marketCap":1448053524},{"date":"2024-07-26","current":-7.10513,"twenty":-8.504633,"median":-8.029564,"eighty":-7.105677,"marketCap":1448053524},{"date":"2024-08-02","current":-7.109273,"twenty":-8.491002,"median":-8.019114,"eighty":-7.105677,"marketCap":1448053524},{"date":"2024-08-09","current":-7.033842,"twenty":-8.475712,"median":-7.991974,"eighty":-7.097834,"marketCap":1442238048},{"date":"2024-08-16","current":-6.879903,"twenty":-8.451599,"median":-7.985142,"eighty":-7.095806,"marketCap":1411222176},{"date":"2024-08-23","current":-6.041633,"twenty":-8.425625,"median":-7.981406,"eighty":-7.090359,"marketCap":1244511864},{"date":"2024-08-30","current":-6.047183,"twenty":-8.418914,"median":-7.97694,"eighty":-7.085583,"marketCap":1219311468},{"date":"2024-09-06","current":-6.034663,"twenty":-8.411646,"median":-7.942728,"eighty":-7.024202,"marketCap":1217372976},{"date":"2024-09-13","current":-6.050501,"twenty":-8.400619,"median":-7.919793,"eighty":-6.989131,"marketCap":1217372976},{"date":"2024-09-20","current":-5.899508,"twenty":-8.390451,"median":-7.809695,"eighty":-6.977241,"marketCap":1194111072},{"date":"2024-09-27","current":-5.635763,"twenty":-8.383344,"median":-7.722148,"eighty":-6.974189,"marketCap":1147587264},{"date":"2024-10-04","current":-6.646499,"twenty":-8.371665,"median":-7.71452,"eighty":-6.971914,"marketCap":1347251940},{"date":"2024-10-10","current":-6.670566,"twenty":-8.369919,"median":-7.665604,"eighty":-6.970443,"marketCap":1343374956},{"date":"2024-10-18","current":-5.989499,"twenty":-8.366581,"median":-7.61103,"eighty":-6.964903,"marketCap":1199926548},{"date":"2024-10-25","current":-5.941495,"twenty":-8.363757,"median":-7.592567,"eighty":-6.963278,"marketCap":1190234088},{"date":"2024-11-01","current":-5.753759,"twenty":-8.362581,"median":-7.48471,"eighty":-6.932913,"marketCap":1153402740},{"date":"2024-11-08","current":-5.323409,"twenty":-8.352088,"median":-7.478194,"eighty":-6.706839,"marketCap":1062293616},{"date":"2024-11-15","current":-4.810927,"twenty":-8.344312,"median":-7.39462,"eighty":-6.66868,"marketCap":949861080},{"date":"2024-11-22","current":-4.597104,"twenty":-8.320901,"median":-7.288282,"eighty":-6.614502,"marketCap":907214256},{"date":"2024-11-29","current":-4.511723,"twenty":-8.314189,"median":-7.193914,"eighty":-6.4628,"marketCap":889767828},{"date":"2024-12-06","current":-3.832688,"twenty":-8.309887,"median":-7.189483,"eighty":-6.054759,"marketCap":754073388},{"date":"2024-12-13","current":-3.741546,"twenty":-8.30727,"median":-7.147179,"eighty":-6.049837,"marketCap":734688468},{"date":"2024-12-20","current":-3.946605,"twenty":-8.303428,"median":-7.141207,"eighty":-6.034627,"marketCap":771519816},{"date":"2024-12-27","current":-6.936731,"twenty":-8.302316,"median":-7.140369,"eighty":-6.034555,"marketCap":1355005908},{"date":"2025-01-03","current":-7.8123,"twenty":-8.301863,"median":-7.141207,"eighty":-6.034663,"marketCap":1527531696},{"date":"2025-01-10","current":-7.782302,"twenty":-8.301426,"median":-7.145546,"eighty":-6.036057,"marketCap":1515900744},{"date":"2025-01-17","current":-7.348445,"twenty":-8.300831,"median":-7.189317,"eighty":-6.042743,"marketCap":1432545588},{"date":"2025-01-24","current":-7.302687,"twenty":-8.300293,"median":-7.192391,"eighty":-6.047847,"marketCap":1432545588},{"date":"2025-01-28","current":-7.264616,"twenty":-8.299451,"median":-7.229265,"eighty":-6.049174,"marketCap":1432545588},{"date":"2025-02-07","current":-7.236748,"twenty":-8.296655,"median":-7.256521,"eighty":-6.050501,"marketCap":1418976144},{"date":"2025-02-14","current":-6.936954,"twenty":-8.289567,"median":-7.234585,"eighty":-6.050566,"marketCap":1356944400},{"date":"2025-02-21","current":-6.209204,"twenty":-8.280918,"median":-7.193914,"eighty":-6.051176,"marketCap":1221249960},{"date":"2025-02-28","current":-5.735312,"twenty":-8.276823,"median":-7.189483,"eighty":-6.049174,"marketCap":1124325360},{"date":"2025-03-07","current":-4.382772,"twenty":-8.275728,"median":-7.147179,"eighty":-6.034591,"marketCap":862628940},{"date":"2025-03-14","current":-4.381178,"twenty":-8.27337,"median":-7.141207,"eighty":-6.005336,"marketCap":862628940},{"date":"2025-03-21","current":-4.382899,"twenty":-8.271865,"median":-7.139645,"eighty":-5.976203,"marketCap":862628940},{"date":"2025-03-28","current":-6.03007,"twenty":-8.267559,"median":-7.132215,"eighty":-5.958282,"marketCap":1184418612},{"date":"2025-04-03","current":-12.27285,"twenty":-8.275893,"median":-7.137062,"eighty":-5.959979,"marketCap":1279404720},{"date":"2025-04-11","current":-11.044555,"twenty":-8.297306,"median":-7.141207,"eighty":-5.971601,"marketCap":1143710280},{"date":"2025-04-17","current":-8.683774,"twenty":-8.301426,"median":-7.143912,"eighty":-5.986226,"marketCap":901398780},{"date":"2025-04-25","current":-8.769575,"twenty":-8.306866,"median":-7.147536,"eighty":-5.989499,"marketCap":911091240},{"date":"2025-05-02","current":-8.750975,"twenty":-8.320901,"median":-7.189649,"eighty":-5.997241,"marketCap":911091240},{"date":"2025-05-09","current":-8.320184,"twenty":-8.320865,"median":-7.193914,"eighty":-5.999307,"marketCap":872321400},{"date":"2025-05-16","current":-7.720916,"twenty":-8.320762,"median":-7.234585,"eighty":-6.005336,"marketCap":816105132},{"date":"2025-05-23","current":-7.734459,"twenty":-8.320415,"median":-7.256521,"eighty":-6.010152,"marketCap":819982116},{"date":"2025-05-30","current":-7.700604,"twenty":-8.317297,"median":-7.263991,"eighty":-6.01222,"marketCap":819982116},{"date":"2025-06-06","current":-7.681007,"twenty":-8.314485,"median":-7.286363,"eighty":-6.02333,"marketCap":819982116},{"date":"2025-06-13","current":-9.456792,"twenty":-8.320762,"median":-7.288884,"eighty":-6.03007,"marketCap":1009954332},{"date":"2025-06-20","current":-9.38443,"twenty":-8.354671,"median":-7.302687,"eighty":-6.032718,"marketCap":1000261872},{"date":"2025-06-27","current":-8.886685,"twenty":-8.370356,"median":-7.33658,"eighty":-6.034591,"marketCap":949861080},{"date":"2025-07-04","current":-8.886268,"twenty":-8.400619,"median":-7.39462,"eighty":-6.034663,"marketCap":949861080},{"date":"2025-07-11","current":-9.439834,"twenty":-8.450162,"median":-7.477671,"eighty":-6.037451,"marketCap":1008015840},{"date":"2025-07-18","current":-10.71898,"twenty":-8.504633,"median":-7.483524,"eighty":-6.043853,"marketCap":1143710280},{"date":"2025-07-25","current":-10.354306,"twenty":-8.575353,"median":-7.586326,"eighty":-6.04851,"marketCap":1108817424},{"date":"2025-08-01","current":-10.200109,"twenty":-8.700378,"median":-7.607601,"eighty":-6.050501,"marketCap":1085555520},{"date":"2025-08-08","current":-10.174658,"twenty":-8.73051,"median":-7.6347,"eighty":-6.050545,"marketCap":1085555520},{"date":"2025-08-15","current":-10.189926,"twenty":-8.755577,"median":-7.668855,"eighty":-6.050988,"marketCap":1085555520},{"date":"2025-08-22","current":-10.404516,"twenty":-8.778653,"median":-7.696508,"eighty":-6.053156,"marketCap":1104940440},{"date":"2025-08-29","current":-12.496435,"twenty":-8.886268,"median":-7.699076,"eighty":-6.05556,"marketCap":1066170600},{"date":"2025-09-05","current":-12.508831,"twenty":-8.917527,"median":-7.704882,"eighty":-6.055623,"marketCap":1066170600},{"date":"2025-09-12","current":-12.713379,"twenty":-9.283082,"median":-7.709288,"eighty":-6.056629,"marketCap":1085555520},{"date":"2025-09-19","current":-13.812899,"twenty":-9.372197,"median":-7.711903,"eighty":-6.091088,"marketCap":1178603136},{"date":"2025-09-26","current":-15.488824,"twenty":-9.421871,"median":-7.713577,"eighty":-6.168118,"marketCap":1318174560},{"date":"2025-10-03","current":-15.429223,"twenty":-9.439834,"median":-7.716349,"eighty":-6.209251,"marketCap":1316236068},{"date":"2025-10-10","current":-15.542765,"twenty":-9.48241,"median":-7.718907,"eighty":-6.209438,"marketCap":1323990036},{"date":"2025-10-17","current":-15.463777,"twenty":-9.516549,"median":-7.722508,"eighty":-6.564001,"marketCap":1316236068},{"date":"2025-10-24","current":-16.141138,"twenty":-9.993637,"median":-7.727404,"eighty":-6.587794,"marketCap":1374390828},{"date":"2025-10-31","current":-15.935241,"twenty":-10.174658,"median":-7.732892,"eighty":-6.604283,"marketCap":1358882892},{"date":"2025-11-07","current":-15.945201,"twenty":-10.180758,"median":-7.758053,"eighty":-6.609789,"marketCap":1358882892},{"date":"2025-11-14","current":-15.900146,"twenty":-10.200109,"median":-7.784219,"eighty":-6.614502,"marketCap":1358882892},{"date":"2025-11-21","current":-16.089098,"twenty":-10.29964,"median":-7.809695,"eighty":-6.640318,"marketCap":1374390828},{"date":"2025-11-28","current":-16.030869,"twenty":-10.386607,"median":-7.849274,"eighty":-6.646499,"marketCap":1374390828},{"date":"2025-12-05","current":-16.003355,"twenty":-10.404516,"median":-7.919793,"eighty":-6.658209,"marketCap":1374390828},{"date":"2025-12-12","current":-15.973808,"twenty":-10.577045,"median":-7.942728,"eighty":-6.66868,"marketCap":1374390828},{"date":"2025-12-19","current":-15.93625,"twenty":-10.714182,"median":-7.97694,"eighty":-6.670691,"marketCap":1374390828},{"date":"2025-12-24","current":-15.662693,"twenty":-10.90375,"median":-7.980005,"eighty":-6.674625,"marketCap":1355005908},{"date":"2026-01-02","current":-17.543083,"twenty":-11.095447,"median":-7.982691,"eighty":-6.684863,"marketCap":1523654712},{"date":"2026-01-09","current":-17.49951,"twenty":-11.336885,"median":-7.988022,"eighty":-6.703505,"marketCap":1523654712},{"date":"2026-01-16","current":-17.442827,"twenty":-12.451475,"median":-7.994219,"eighty":-6.740071,"marketCap":1523654712},{"date":"2026-01-23","current":-17.215232,"twenty":-12.506134,"median":-8.02019,"eighty":-6.870823,"marketCap":1502331300},{"date":"2026-01-30","current":-17.402236,"twenty":-12.672793,"median":-8.041443,"eighty":-6.879903,"marketCap":1525593204},{"date":"2026-02-06","current":-16.762691,"twenty":-13.116393,"median":-8.071832,"eighty":-6.881774,"marketCap":1473253920},{"date":"2026-02-12","current":-15.877471,"twenty":-13.585714,"median":-8.127348,"eighty":-6.88926,"marketCap":1403468208}],"updateTime":1770949902736},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02496\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1177219782","title":"Wuhan YZY Biopharma (2496) Releases Further Details on Land and Building Transfer","url":"https://stock-news.laohu8.com/highlight/detail?id=1177219782","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177219782?lang=en_us&edition=fundamental","pubTime":"2026-02-05 18:24","pubTimestamp":1770287090,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma (2496) has provided additional information regarding the transfer of a land use right and building, originally intended for manufacturing facilities related to the company’s...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"gpt_icon":0},{"id":"2609739043","title":"Wuhan Yzy Biopharma Sells Land Use Right and Building","url":"https://stock-news.laohu8.com/highlight/detail?id=2609739043","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609739043?lang=en_us&edition=fundamental","pubTime":"2026-02-05 18:16","pubTimestamp":1770286602,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co. Ltd. has announced the transfer of a land use right and building originally acquired in 2012 for manufacturing purposes. Due to delays and changes in operational needs, the assets are no longer required for their intended use. The company states that the transaction will not impact its business plans, R&D, or commercialisation activities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDLCFs3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"gpt_icon":0},{"id":"1154432089","title":"YZYBIO-B (02496) Receives HKEX Approval for Full H-Share Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1154432089","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154432089?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:15","pubTimestamp":1770214501,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) announced that the company has obtained approval from the Hong Kong Stock Exchange on February 4, 2026, for the listing and trading of 68.0103 million H-shares. This amount is equivalent to the total number of the company's non-listed shares to be converted and listed.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2608369805","title":"Wuhan Yzy Biopharma Says M701 Receives IND Approval From FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2608369805","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608369805?lang=en_us&edition=fundamental","pubTime":"2026-02-04 00:33","pubTimestamp":1770136418,"startTime":"0","endTime":"0","summary":"Feb 3 (Reuters) - Wuhan YZY Biopharma Co Ltd <2496.HK>::*M701 RECEIVES IND APPROVAL FROM FDA*Further company coverage: 2496.HK* ((Reuters.Briefs@thomsonreuters.com;))  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-FEB-202616:20:19 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nRSD1mMXJx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2608827589","title":"Wuhan YZY Biopharma Gets Trial Nod for Malignant Pleural Effusion Drug from US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2608827589","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608827589?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:57","pubTimestamp":1770116271,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma  obtained clinical trial approval for the investigational new drug application for M701 from the US Food and Drug Administration , according to a Tuesday Hong Kong bourse filing.The drug is indicated for malignant pleural effusion , which is a common and severe complication of malignant tumors, particularly in advanced lung and breast cancer patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"1161842676","title":"YZYBIO-B (02496): M 701 Receives FDA IND Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1161842676","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161842676?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:14","pubTimestamp":1770113661,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) announced that on January 31, 2026, the Investigational New Drug (IND) application for Recombinant Anti-EpCAM and CD3 Human-Mouse Chimeric Bispecific Antibody for Injection (M 701)...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496","IND"],"gpt_icon":0},{"id":"2608782493","title":"Wuhan YZY Biopharma - M701 Receives Ind Approval From FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2608782493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608782493?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:06","pubTimestamp":1770113215,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ07F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2608954824","title":"Wuhan YZY Biopharma Receives FDA IND Approval for M701 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2608954824","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608954824?lang=en_us&edition=fundamental","pubTime":"2026-02-03 18:06","pubTimestamp":1770113209,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. announced that its Investigational New Drug  application for M701, a recombinant anti-epithelial cell adhesion molecule  and anti-cluster of differentiation 3  human-mouse chimeric bispecific antibody, has been approved by the U.S. Food and Drug Administration  for clinical trials. The approved study is an open-label, multicenter, phase Ib/II trial to evaluate the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of intrapleurally administered M701 in patients with malignant pleural effusion  caused by advanced epithelial tumors. The company noted that there is no guarantee M701 will ultimately be successfully developed and marketed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL89WnXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"gpt_icon":0},{"id":"1114325741","title":"YZYBIO-B (02496): China Securities Regulatory Commission Issues Filing Notice for Company's H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1114325741","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114325741?lang=en_us&edition=fundamental","pubTime":"2026-01-26 18:10","pubTimestamp":1769422213,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) has released an announcement stating that the company recently submitted a filing to the China Securities Regulatory Commission (CSRC) regarding the full circulation of its H-shares....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2606221663","title":"Wuhan YZY Biopharma Submits CSRC Filing for H Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2606221663","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606221663?lang=en_us&edition=fundamental","pubTime":"2026-01-26 17:58","pubTimestamp":1769421528,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. has announced that it has submitted a filing to the China Securities Regulatory Commission  regarding the proposed implementation of H share full circulation. The company has applied to the CSRC for the conversion of 68,010,299 domestic shares into H shares. The H share full circulation and the conversion and listing process have not yet been finalized and remain subject to further procedures and approvals from the CSRC, the Hong Kong Stock Exchange, and other relevant regulatory authorities. The company will provide further updates on the progress as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief via ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL7XVjYS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2606294481","title":"Wuhan Yzy Biopharma Sells Land Use Right and Building to Wuhan Yiruide","url":"https://stock-news.laohu8.com/highlight/detail?id=2606294481","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606294481?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:11","pubTimestamp":1769411487,"startTime":"0","endTime":"0","summary":"Wuhan Yzy Biopharma Co. Ltd. has announced a discloseable transaction involving the transfer of land use rights and buildings to Wuhan Yiruide Medical Treatment Equipment New Technology Co., Ltd. The transaction, formalized through a transfer agreement signed on January 23, 2026, includes approximately 11,333.22 square meters of gross floor area. The deal is classified as a discloseable transaction under Hong Kong Stock Exchange Listing Rules.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 23, 2026, and is solely responsible for the information contai","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL5YHGxj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2605409700","title":"BRIEF-Wuhan YZY Biopharma Says Wuhan Yiruide To Buy Land Use Right And Building","url":"https://stock-news.laohu8.com/highlight/detail?id=2605409700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605409700?lang=en_us&edition=fundamental","pubTime":"2026-01-23 23:19","pubTimestamp":1769181566,"startTime":"0","endTime":"0","summary":"BRIEF-Wuhan YZY Biopharma Says Wuhan Yiruide To Buy Land Use Right And BuildingJan 23  - Wuhan YZY Biopharma Co Ltd 2496.HK:WUHAN YIRUIDE TO BUY LAND USE RIGHT AND BUILDING FOR RMB36.9 MILLIONLAND SITUATED AT EAST LAKE NEW TECHNOLOGY DEVELOPMENT ZONE, WUHAN, HUBEI PROVINCEFurther company coverage: 2496.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO0NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"gpt_icon":0},{"id":"1110658902","title":"YZYBIO-B (02496) Plans to Transfer Land Use Rights and Buildings in Wuhan East Lake High-Tech Zone for RMB 36.88 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1110658902","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110658902?lang=en_us&edition=fundamental","pubTime":"2026-01-23 22:10","pubTimestamp":1769177422,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) announced that on January 23, 2026, Wuhan Yiruid entered into a transfer agreement with the company, pursuant to which the company agreed to transfer its land use rights and...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"gpt_icon":0},{"id":"1155714027","title":"Wuhan YZY Biopharma (2496) Announces Discloseable Transaction for Transferring Land Use Right and Building to Wuhan Yiruide","url":"https://stock-news.laohu8.com/highlight/detail?id=1155714027","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155714027?lang=en_us&edition=fundamental","pubTime":"2026-01-23 22:03","pubTimestamp":1769177034,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. (Stock Code: 2496) entered into a transfer agreement on January 23, 2026, with Wuhan Yiruide Medical Treatment Equipment New Technology Co., Ltd. to dispose of a land...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496"],"gpt_icon":0},{"id":"2605404403","title":"Wuhan YZY Biopharma Co Ltd - Wuhan Yiruide to Buy Land Use Right and Building for RMB36.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2605404403","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605404403?lang=en_us&edition=fundamental","pubTime":"2026-01-23 22:03","pubTimestamp":1769177009,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO0NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"1138960874","title":"YZYBIO-B (02496): Shi Jian Elected as Employee Representative Supervisor","url":"https://stock-news.laohu8.com/highlight/detail?id=1138960874","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138960874?lang=en_us&edition=fundamental","pubTime":"2025-12-31 12:58","pubTimestamp":1767157097,"startTime":"0","endTime":"0","summary":"Dr. Wang Tao has resigned from his position as Employee Representative Supervisor of the company for personal career development reasons, effective December 31, 2025. Dr. Shi Jian, Director of the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2595728216","title":"Wuhan YZY Biopharma Appoints New Employee Representative Supervisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2595728216","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595728216?lang=en_us&edition=fundamental","pubTime":"2025-12-31 12:53","pubTimestamp":1767156820,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co. Ltd. has announced the resignation of Dr. Wang Tao as employee representative supervisor and the appointment of Dr. Shi as the new employee representative supervisor. The company’s board and its composition remain otherwise unchanged.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL1dl924:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02496","BK1161"],"gpt_icon":0},{"id":"1108970514","title":"YZYBIO-B (02496): Y225 (Emicizumab Injection) Receives IND Approval from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1108970514","media":"Stock News","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108970514?lang=en_us&edition=fundamental","pubTime":"2025-12-24 19:38","pubTimestamp":1766576310,"startTime":"0","endTime":"0","summary":"YZYBIO-B (02496) announced on December 23, 2025, that its biosimilar drug Y225 has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA). Y225...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","02496","BK1161"],"gpt_icon":0},{"id":"2593471343","title":"Wuhan YZY Biopharma  - Y225 ‘‘Emicizumab Injection\" Receives Ind Approval From Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2593471343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593471343?lang=en_us&edition=fundamental","pubTime":"2025-12-24 19:33","pubTimestamp":1766576028,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nFWN3XU03D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2593713404","title":"Wuhan YZY Biopharma Receives NMPA IND Approval for Y225 Emicizumab Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2593713404","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593713404?lang=en_us&edition=fundamental","pubTime":"2025-12-24 19:33","pubTimestamp":1766576009,"startTime":"0","endTime":"0","summary":"Wuhan YZY Biopharma Co., Ltd. has announced that its Y225 \"Emicizumab Injection\" has received Investigational New Drug  approval from the National Medical Products Administration  of China. The approved clinical trial will evaluate the bioequivalence of Hemlibra and Y225 in healthy adult male subjects. This milestone positions Y225 as a potential first biosimilar of Hemlibra to be launched in China, aiming to address the domestic gap in high-barrier bispecific monoclonal antibody biosimilars.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 24, 2025, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDL2hMmWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02496"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}